CD44 and EGFR Dual-Targeted Antibody-Recruiting Complex Based on Hyaluronic Acid Grafted with β-Cyclodextrin and Multivalent Rhamnose for Cancer Immunotherapy

Abstract

A new generation of multivalent antibody-recruiting molecules (ARMs) with dual-targeting tumor-binding termini (TBT), including hyaluronic acid targeting CD44 and nanobody 7D12 or peptide GE11 targeting EGFR, was constructed for cancer immunotherapy. The 7D12 or GE11 were assembled onto β-cyclodextrin-grafted hyaluronic acid (HACD) with multivalent rhamnose via host-guest interaction to form macromolecule complexes. The immunological studies proved that these complexes had dual-targetability on CD44 and EGFR and the rhamnose on HACD could recruit anti-Rha antibodies to mediate cytotoxicity against the targeted tumor cells. This bispecific ARM strategy provides a platform for cancer immunotherapy.

Key words

antibody-recruiting complex - cancer immunotherapy - dual-targeting - hyaluronic acid - host-guest interaction - 7D12 - GE11

Publication History

Received: 21 March 2023

Accepted after revision: 15 May 2023

Accepted Manuscript online:
15 May 2023

Article published online:
14 June 2023

• References

• 1a Lake BP. M, Wylie RG, Barinka C, Rullo AF. Angew. Chem. Int. Ed. 2023; 62: e202214659
• 1b Sasaki K, Muguruma K, Osawa R, Fukuda A, Taniguchi A, Kishimura A, Hayashi Y, Mori T, Katayama Y. RSC Med. Chem. 2021; 12: 406
• 2 Rullo AF, Fitzgerald KJ, Muthusamy V, Liu M, Yuan C, Huang MD, Kim M, Cho AE, Spiegel DA. Angew. Chem. Int. Ed. 2016; 55: 3642
• 3a De Coen R, Nuhn L, Perera C, Arista-Romero M, Risseeuw MD. P, Freyn A, Nachbagauer R, Albertazzi L, Van Calenbergh S, Spiegel DA, Peterson BR, De Geest BG. Biomacromolecules 2020; 21: 793
• 3b Dubacheva GV, Curk T, Frenkel D, Richter RP. J. Am. Chem. Soc. 2019; 141: 2577
• 4 Uvyn A, De Coen R, Gruijs M, Tuk CW, De Vrieze J, van Egmond M, De Geest BG. Angew. Chem. Int. Ed. 2019; 58: 12988
• 5 Liet B, Laigre E, Goyard D, Todaro B, Tiertant C, Boturyn D, Berthet N, Renaudet O. Chem. Eur. J. 2019; 25: 15508
• 6 Elamin KM, Motoyama K, Higashi T, Yamashita Y, Tokuda A, Arima H. Int. J. Biol. Macromol. 2018; 113: 386
• 7a Singh P, Chen Y, Tyagi D, Wu L, Ren X, Feng J, Carrier A, Luan T, Tang Y, Zhang J, Zhang X. Int. J. Pharm. 2021; 602: 120602
• 7b Dubacheva GV, Curk T, Auzely-Velty R, Frenkel D, Richter RP. Proc. Natl. Acad. Sci. U.S.A. 2015; 112: 5579
• 8 Lin H, Zhou K, Li D, Hong HF, Xie YT, Gong L, Shen Y, Zhou ZF, Shi J, Wu ZM. ChemMedChem 2021; 16: 2960
• 9 Bridge T, Shaikh SA, Thomas P, Botta J, McCormick PJ, Sachdeva A. Angew. Chem. Int. Ed. 2019; 58: 17986
• 10 Pi J, Jiang J, Cai H, Yang F, Jin H, Yang P, Cai J, Chen ZW. Drug Deliv. 2017; 24: 1549
• 11 Lin H, Hong H, Wang J, Li C, Zhou Z, Wu Z. Chem. Commun. 2020; 56: 13959
• 12 Hong H, Zhou Z, Zhou K, Liu S, Guo Z, Wu Z. Chem. Sci. 2019; 10: 9331
• 13 Hong H, Li C, Gong L, Wang J, Li D, Shi J, Zhou Z, Huang Z, Wu Z. Chem. Sci. 2021; 12: 4623
• 14 Liu D, Jin F, Shu G, Xu X, Qi J, Kang X, Yu H, Lu K, Jiang S, Han F, You J, Du Y, Ji J. J. Biomater. 2019; 211: 57
• 15a Cho EJ, Sun B, Doh KO, Wilson EM, Torregrosa-Allen S, Elzey BD, Yeo Y. Biomaterials 2015; 37: 312
• 15b Ganta S, Singh A, Kulkarni P, Keeler AW, Piroyan A, Sawant RR, Patel NR, Davis B, Ferris C, O’Neal S, Zamboni W, Amiji MM, Coleman TP. Pharm. Res. 2015; 32: 2753
• 16 Yu H, Lin H, Xie Y, Qu M, Jiang M, Shi J, Hong H, Xu H, Li L, Liao G, Wu Z, Zhou Z. Chin. Chem. Lett. 2022; 33: 4882
• 17 Zhou K, Hong H, Lin H, Gong L, Li D, Shi J, Zhou Z, Xu F, Wu Z. J. Med. Chem. 2022; 65: 323
• 18 Hong H, Lin H, Li D, Gong L, Zhou K, Li Y, Yu H, Zhao K, Shi J, Zhou Z, Huang Z, Wu Z. Angew. Chem. Int. Ed. 2022; 61: e202208773
• 19 Oh EJ, Choi JS, Kim H, Joo CK, Hahn SK. Biomaterials 2011; 32: 3115
• 20 Liu J, Hong H, Shi J, Xie Y, Lu Z, Liu Z, Zhou Z, Bian Z, Huang Z, Wu Z. Eur. J. Pharm. Sci. 2021; 165: 105941
• 21 Li Y, Gong L, Hong H, Lin H, Li D, Shi J, Zhou Z, Wu Z. Chem. Commun. 2022; 58: 2568